Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a su...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ros Chapman, Michiel van Diepen, Nicola Douglass, Shireen Galant, Mohamed Jaffer, Emmanuel Margolin, Phindile Ximba, Tandile Hermanus, Penny L. Moore, Anna-Lise Williamson
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	LSDV lumpy skin disease vaccine HIV-1 vector poxvirus Medicine R
Acceso en línea:	https://doaj.org/article/d074567c87694c7faae8bcca2f87c8b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d074567c87694c7faae8bcca2f87c8b7
record_format	dspace
spelling	oai:doaj.org-article:d074567c87694c7faae8bcca2f87c8b72021-11-25T19:10:55ZAssessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV10.3390/vaccines91112812076-393Xhttps://doaj.org/article/d074567c87694c7faae8bcca2f87c8b72021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1281https://doaj.org/toc/2076-393XThe modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5.Ros ChapmanMichiel van DiepenNicola DouglassShireen GalantMohamed JafferEmmanuel MargolinPhindile XimbaTandile HermanusPenny L. MooreAnna-Lise WilliamsonMDPI AGarticleLSDVlumpy skin diseasevaccineHIV-1vectorpoxvirusMedicineRENVaccines, Vol 9, Iss 1281, p 1281 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	LSDV lumpy skin disease vaccine HIV-1 vector poxvirus Medicine R
spellingShingle	LSDV lumpy skin disease vaccine HIV-1 vector poxvirus Medicine R Ros Chapman Michiel van Diepen Nicola Douglass Shireen Galant Mohamed Jaffer Emmanuel Margolin Phindile Ximba Tandile Hermanus Penny L. Moore Anna-Lise Williamson Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
description	The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5.
format	article
author	Ros Chapman Michiel van Diepen Nicola Douglass Shireen Galant Mohamed Jaffer Emmanuel Margolin Phindile Ximba Tandile Hermanus Penny L. Moore Anna-Lise Williamson
author_facet	Ros Chapman Michiel van Diepen Nicola Douglass Shireen Galant Mohamed Jaffer Emmanuel Margolin Phindile Ximba Tandile Hermanus Penny L. Moore Anna-Lise Williamson
author_sort	Ros Chapman
title	Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
title_short	Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
title_full	Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
title_fullStr	Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
title_full_unstemmed	Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
title_sort	assessment of an lsdv-vectored vaccine for heterologous prime-boost immunizations against hiv
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d074567c87694c7faae8bcca2f87c8b7
work_keys_str_mv	AT roschapman assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT michielvandiepen assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT nicoladouglass assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT shireengalant assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT mohamedjaffer assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT emmanuelmargolin assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT phindileximba assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT tandilehermanus assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT pennylmoore assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv AT annalisewilliamson assessmentofanlsdvvectoredvaccineforheterologousprimeboostimmunizationsagainsthiv
_version_	1718410245531762688

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

Ejemplares similares